Notified cases of mpox in the city of Rio de Janeiro, Brazil: a descriptive study, 2022

OBJECTIVE

To describe the profile of cases of mpox in the city of Rio de Janeiro between June and November 2022.

METHODS

This was a descriptive study of secondary data obtained from mpox notification forms. Socioeconomic, clinical and spatial data were analyzed.

RESULTS

Of the 928 cases, 93.7% were male, 85.0% cisgender male, 65.6% homosexual, 41.8% between 30 and 39 years old, and 41.0% were of White race/skin color. A total of 34.5% had immunosuppression due to illness, and 41.9% reported their HIV status as being positive. The most prevalent signs and symptoms were: skin lesions (96.6%), especially with multiple manifestations (67.8%) in the genital region (46.1%), in addition to fever (58.3%), adenomegaly (43.3%) and headache (38.7%). Most notifications occurred in public services (81.3%) and in hospital care (51.3%).

CONCLUSION

The study revealed high incidence of mpox, especially among young, cisgender and homosexual men. Most cases were mild, with genital lesions, progressing to cure without hospitalization. Person-to-person transmission was predominant.

Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: a cohort study from Brazil

BACKGROUND

COVID-19 vaccines have been shown to protect pregnant individuals against mild and severe COVID-19 outcomes. However, limited safety data are available for inactivated (CoronaVac) and mRNA (BNT162b2) vaccines during pregnancy regarding their effect on birth outcomes and neonatal mortality, especially in low- and middle-income countries.

METHODS

We conducted a retrospective population-based cohort study in Rio de Janeiro, Brazil, with 17 513 singleton live births conceived between 15 May 2021 and 23 October 2021. The primary exposure was maternal vaccination with CoronaVac or mRNA BNT162b2 vaccines and sub-analyses were performed by the gestational trimester of the first dose and the number of doses given during pregnancy. The outcomes were pre-term birth (PTB), small for gestational age (SGA), low birthweight (LBW), low Apgar 5 and neonatal death. We used the Cox model to estimate the hazard ratio (HR) with a 95% CI and applied the inverse probability of treatment weights to generate adjusted HRs.

RESULTS

We found no significant increase in the risk of PTB (HR: 0.98; 95% CI 0.88, 1.10), SGA (HR: 1.09; 95% CI 0.96, 1.27), LBW (HR: 1.00; 95% CI 0.88, 1.14), low Apgar 5 (HR: 0.81; 95% CI 0.55, 1.22) or neonatal death (HR: 0.88; 95% CI 0.56, 1.48) in women vaccinated with CoronaVac or BNT162b2 vaccines. These findings were consistent across sub-analyses stratified by the gestational trimester of the first dose and the number of doses given during pregnancy. We found mild yet consistent protection against PTB in women who received different vaccine platforms during the third trimester of pregnancy (any vaccines, HR: 0.78; 95% CI 0.63, 0.98; BNT162b2, HR: 0.75; 95% CI 0.59, 0.99).

CONCLUSIONS

This study provides evidence that COVID-19 vaccination in all trimesters of pregnancy, irrespective of the vaccine type, is safe and does not increase the risk of adverse birth outcomes or neonatal deaths.

Factors associated with COVID-19 vaccination among pregnant women in Rio De Janeiro City, Brazil

COVID-19 vaccination during pregnancy is safe and effective in reducing the risk of complications. However, the uptake is still below targets worldwide. This study aimed to explore the factors associated with COVID-19 vaccination uptake among pregnant women since data on this topic is scarce in low-to-middle-income countries. A retrospective cohort study included linked data on COVID-19 vaccination and pregnant women who delivered a singleton live birth from August 1, 2021, to July 31, 2022, in Rio de Janeiro City, Brazil. Multiple logistic regression was performed to identify factors associated with vaccination during pregnancy, applying a hierarchical model and describing odds ratio with 95% confidence intervals. Of 65,304 pregnant women included in the study, 53.0% (95% CI, 52-53%) received at least one dose of COVID-19 vaccine during pregnancy. Higher uptake was observed among women aged older than 34 (aOR 1.21, 95%CI 1.15-1.28), black (aOR 1.10, 1.04-1.16), or parda/brown skin colour (aOR 1.05, 1.01-1.09), with less than eight years of education (aOR 1.09, 1.02-1.17), living without a partner (aOR 2.24, 2.16-2.34), more than six antenatal care appointments (aOR 1.92, 1.75-2.09), and having a previous child loss (OR 1.06, 1.02-1.11). These results highlight the need for targeted educational campaigns, trustful communication, and accessibility strategies for specific populations to improve vaccination uptake during pregnancy.

Excess mortality from all causes during the COVID-19 pandemic in the city of Rio de Janeiro, Brazil

OBJECTIVE

To evaluate excess mortality in the city of Rio de Janeiro, Brazil, due to the COVID-19 pandemic (March 2020 to January 2022).

METHODS

Ecological study using secondary data from the Brazilian Mortality Information System, having the city of Rio de Janeiro as the unit of analysis. Excess mortality was estimated by the difference between the mean number of all expected deaths and the mean number of observed deaths, considering the 2015-2019 period. The quantile regression method was adjusted. The total value of cases above that expected by the historical series was estimated. Among all deaths, cases of COVID-19 and Influenza as underlying causes of death were selected. The ratio between excess mortality and deaths due to COVID-19 was calculated.

RESULTS

We identified an excess of 31,920 deaths by the mean (increase of 26.8%). The regression pointed to 31,363 excess deaths. We found 33,401 deaths from COVID-19 and 176 deaths from Influenza. The ratio between the verified excess mortality and deaths due to COVID-19 was 0.96 by the mean and 0.95 by the regression.

CONCLUSION

The study pointed to large excess deaths during the COVID-19 pandemic in the city of Rio de Janeiro distributed in waves, including the period of the Influenza outbreak.

Excesso de mortalidade por todas as causas na pandemia de COVID-19 no município do Rio de Janeiro (RJ)

RESUMO Objetivo: Analisar o excesso de óbitos no município do Rio de Janeiro (MRJ), RJ, durante a pandemia de COVID-19 (março de 2020 a janeiro de 2022). Métodos: Foi realizado um estudo ecológico com dados secundários do Sistema de Informação sobre Mortalidade cuja unidade de análise foi o MRJ. O excesso de mortalidade foi calculado pela diferença entre a média de óbitos esperados e a média dos óbitos observados levando-se em conta o período de 2015 a 2019. Foi ajustado um método de regressão quantílica. Calculou-se o valor total dos casos acima do esperado pela série histórica. Foram selecionados os óbitos por causa básica COVID-19 e Influenza. Também foi calculada a razão entre o excesso de óbitos e os óbitos atribuídos à COVID-19. Resultados: Foi identificado excesso de 31.920 óbitos pela média (26,8% de incremento). Pela regressão quantílica, encontrou-se excesso de 31.363 óbitos. Ocorreram 33.401 óbitos por COVID-19 e 176 por Influenza. A razão entre o excesso de óbitos encontrado e os óbitos atribuídos à COVID-19 foi de 0,96 pela média e 0,95 pela regressão quantílica. Conclusão: O estudo apontou grande excesso de óbitos durante a pandemia de COVID-19 no MRJ, distribuído em ondas, incluindo-se o período do surto de Influenza.

Centro de operações de emergência na COVID-19: a experiência do município do Rio de Janeiro

O presente artigo descreve a experiência de implantação de um centro de operações de emergência (COE) para coordenação da resposta à pandemia de COVID-19 no município do Rio de Janeiro, Brasil. Seguindo o modelo de gestão de emergências em saúde pública preconizado pela Organização Mundial da Saúde (OMS), este centro de caráter temporário (COE COVID-19 RIO) foi ativado em janeiro de 2021. O relato foi estruturado com base em cinco eixos temáticos: arcabouço legal; estrutura, planos e procedimentos; articulações institucionais; informações em saúde para apoio decisório; e comunicação de risco. Entre os avanços importantes relacionados ao estabelecimento desta iniciativa, destacaram-se ganhos em governança para a organização do enfrentamento à COVID-19, aumento da sinergia entre setores e instituições, maior compartilhamento de informações em relação às medidas de prevenção e controle da doença, inovação nas análises epidemiológicas e ganhos na transparência e oportunidade na tomada de decisões. Concluiu-se que, mesmo sendo concebido em estágio avançado da pandemia na cidade, o COE COVID-19 RIO teve papel relevante na estruturação da resposta. Ainda, apesar do caráter temporário do COE, a experiência mostrou-se como importante legado para a condução de futuras emergências em saúde pública no município do Rio de Janeiro.